, Azadeh Hajmirza has been the recipient of doctoral funding from the Société Française d'Hématologie. Additional support was from Jannsen-Cilag and Mundipharma

.. P. Bibliography-1, D. Jares, E. Colomer, and . Campo, Molecular pathogenesis of mantle cell lymphoma, The Journal of clinical investigation, vol.122, 2012.

M. H. Delfau-larue, High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma, Blood, vol.126, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02331700

E. M. Hartmann, Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling, Blood, vol.116, p.953, 2010.

B. Meissner, The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma, Blood, vol.121, p.3161, 2013.

R. , Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma, Blood, vol.119, 1963.

J. Zhang, The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells, Blood, vol.123, p.2988, 2014.

R. , Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma, Nature medicine, vol.20, 2014.

S. Bea, Landscape of somatic mutations and clonal evolution in mantle cell lymphoma, Proceedings of the National Academy of Sciences of the United States of America, vol.110, p.18250, 2013.

A. Emadali, Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms, Blood, vol.127, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01920364

S. H. Swerdlow, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, p.2375, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800015

A. Clipson, KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype, Leukemia, vol.29, p.1177, 2015.

D. Chiron, Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma, Cancer discovery, vol.4, p.1022, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02490276

M. A. Dawson, The cancer epigenome: Concepts, challenges, and therapeutic opportunities, Science, vol.355, p.1147, 2017.

P. Nagarajan, Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis, Oncogene, vol.28, p.1053, 2009.

D. Rodriguez, Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia, Blood, vol.126, p.195, 2015.

A. Pastore, Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry, The Lancet. Oncology, vol.16, p.1111, 2015.

. Bibliographie,

E. Campo, The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, pp.5019-5032, 2011.

S. H. Swerdlow, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, pp.2375-2390, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800015

K. E. Smedby and H. Hjalgrim, Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes, Semin. Cancer Biol, vol.21, pp.293-298, 2011.

I. U. Reserves and -. D. Orphanet, Lymphome à cellules du manteau, p.10, 2017.

A. A. Gru, Cutaneous mantle cell lymphoma: a clinicopathologic review of 10 cases, J. Cutan. Pathol, vol.43, pp.1112-1120, 2016.

A. Carvajal-cuenca, In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior, Haematologica, vol.97, pp.270-278, 2012.

J. Taverna, A rare presentation of in situ mantle cell lymphoma and follicular lymphoma: a case report and review of the literature, Case Rep. Hematol, p.145129, 2014.

C. Sloan, Q. Xiong, A. Crivaro, S. Steinman, and A. Bagg, Multifocal mantle cell lymphoma in situ in the setting of a composite lymphoma, Am. J. Clin. Pathol, vol.143, p.307, 2015.

M. Tiemann, Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network, Br. J. Haematol, vol.131, pp.29-38, 2005.

F. Bertoni and M. Ponzoni, The cellular origin of mantle cell lymphoma, Int. J. Biochem. Cell Biol, vol.39, pp.1747-1753, 2007.

P. Jares, D. Colomer, and E. Campo, Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics, Nat. Rev. Cancer, vol.7, pp.750-762, 2007.

Z. Liu, CD5-mantle cell lymphoma, Am. J. Clin. Pathol, vol.118, pp.216-224, 2002.

M. Monteil, M. Callanan, C. Dascalescu, J. J. Sotto, and D. Leroux, Molecular diagnosis of t(11;14) in mantle cell lymphoma using two-colour interphase fluorescence in situ hybridization, Br. J. Haematol, vol.93, pp.656-660, 1996.

I. Salaverria, CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma, Blood, vol.121, pp.1394-1402, 2013.

J. J. Van-dongen, Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936, Leukemia, vol.17, pp.2257-2317, 2003.

E. Flordal-thelander, Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma, Leuk. Res, vol.31, pp.1219-1230, 2007.

E. M. Hartmann, Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling, Blood, vol.116, pp.953-961, 2010.

E. Gimenez, Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est, Etude des Leucémies et Autres Maladies du Sang

, Br. J. Haematol, vol.158, pp.186-197, 2012.

A. Jaspers, Rev. Med. Liege, vol.65, pp.171-176, 2010.

R. Narurkar, M. Alkayem, and D. Liu, SOX11 is a biomarker for cyclin D1-negative mantle cell lymphoma, Biomark. Res, vol.4, p.6, 2016.

A. Mozos, SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype, Haematologica, vol.94, pp.1555-1562, 2009.

M. Lord, A. M. Wasik, B. Christensson, and B. Sander, The utility of mRNA analysis in defining SOX11 expression levels in mantle cell lymphoma and reactive lymph nodes, Haematologica, vol.100, pp.369-372, 2015.

K. Fu, Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling, Blood, vol.106, pp.4315-4321, 2005.

S. Beà, Landscape of somatic mutations and clonal evolution in mantle cell lymphoma, Proc. Natl. Acad. Sci. U. S. A, vol.110, pp.18250-18255, 2013.

B. Meissner, The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma, Blood, vol.121, pp.3161-3164, 2013.

R. Kridel, Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma, Blood, vol.119, pp.1963-1971, 2012.

J. Zhang, The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells, Blood, vol.123, pp.2988-2996, 2014.

R. Rahal, Pharmacological and genomic profiling identifies NF-?B-targeted treatment strategies for mantle cell lymphoma, Nat. Med, vol.20, pp.87-92, 2014.

D. Rossi, A Molecular Model for the Prediction of Progression Free Survival in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation: Results from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL), Blood, vol.126, pp.336-336, 2015.

A. C. Queirós, Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage, Cancer Cell, vol.30, pp.806-821, 2016.

E. Hoster, A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma, Blood, vol.111, pp.558-565, 2008.

E. Hoster, Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.32, pp.1338-1346, 2014.

P. Martin, Outcome of deferred initial therapy in mantle-cell lymphoma, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.27, pp.1209-1213, 2009.

J. M. Vose, Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management, Am. J. Hematol, vol.92, pp.806-813, 2017.

L. Gouill and S. , Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma, N. Engl. J. Med, vol.377, pp.1250-1260, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02329536

M. L. Wang, Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma, N. Engl. J. Med, vol.369, pp.507-516, 2013.

L. Raedler, Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma, Am. Health Drug Benefits, vol.8, pp.135-140, 2015.

D. Chiron, Cell-cycle reprogramming for PI3K inhibition overrides a relapsespecific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma, Cancer Discov, vol.4, pp.1022-1035, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02490276

A. Hajmirza, BET Family Protein BRD4: An Emerging Actor in NF?B Signaling in Inflammation and Cancer, Biomedicines, vol.6, 2018.

M. A. Dawson, The cancer epigenome: Concepts, challenges, and therapeutic opportunities, Science, vol.355, pp.1147-1152, 2017.

P. Nagarajan, Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis, Oncogene, vol.28, pp.1053-1062, 2009.

M. K. Shanmugam, Role of novel histone modifications in cancer, Oncotarget, vol.9, pp.11414-11426, 2017.

A. Pastore, Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry, Lancet Oncol, vol.16, pp.1111-1122, 2015.